肿瘤第一线 · 学术知识传播

MedSci主页 / 所有栏目 / 肿瘤第一线 · 学术知识传播

Am J Clin Nutr:结肠癌患者术前静脉注射ω-3脂肪酸的影响

2021-12-16 MedSci原创 MedSci原创

术后炎症反应有助于组织的愈合和恢复,但过度炎症与术后并发症有关,n-3(ω-3)PUFAs可调节炎症反应,可能有助于防止促炎症级联。本研究旨在探究围术期静脉注射n-3 PUFAs对结肠癌手

术后炎症反应有助于组织的愈合和恢复,但过度炎症与术后并发症有关,n-3(ω-3)PUFAs可调节炎症反应,可能有助于防止促炎症级联。本研究旨在探究围术期静脉注射n-3 PUFAs对结肠癌手术中炎症细胞因子的影响。

本研究是一项随机、双盲、安慰剂对照的临床试验。44名接受非转移癌选择性结肠切除术的患者,随机分配在手术前夜和术后早晨进行2次静脉注射n-3 PUFA或生理盐水对照。在6个围手术期时间点进行血液采样,以了解血清中细胞因子的变化和LPS刺激的全血样本和白细胞膜脂肪酸谱。

结果,23名患者接受生理盐水,21名患者接受n-3 PUFAs。除开放性切除外,各组间患者和手术的特征相同(生理盐水n = 5,n-3 PUFA n = 0,P = 0.056)。LPS刺激后的体外IL-6在术后第一天n-3 PUFA组显著升高(P = 0.014),但在术后第二天无差异(P = 0.467)。术后第4天,n-3 PUFA组的白细胞计数较高(P = 0.029)。n-3 PUFA组有更多的患者出现感染性并发症(8例VS 3例,P = 0.036)。血清IL-6、IL-10、C反应蛋白和住院时间没有总体差异。给予n-3 PUFAs可使白细胞膜n-3 PUFAs含量迅速增加。

总之,该研究结果表明,在n-3 PUFA组中,未发现与血清和LPS刺激的细胞因子有明显关系,但出乎意料的是,发生了更多的感染性并发症。因此,在本研究范围内,围手术期静脉注射n-3 PUFA乳剂作为独立输液在原发性吻合术的结肠切除术中的非标使用需要谨慎。

原始出处:

Nathalie Bakker, Rick S van den Helder, et al., Effects of perioperative intravenous ω-3 fatty acids in colon cancer patients: a randomized, double-blind, placebo-controlled clinical trial. Am J Clin Nutr. 2020 Feb 1;111(2):385-395. doi: 10.1093/ajcn/nqz281.

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1698307, encodeId=6052169830ea4, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Oct 12 11:14:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779194, encodeId=837a1e7919411, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Mon Jan 17 14:14:20 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778818, encodeId=5a6b1e7881865, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Mon Oct 10 07:14:20 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329901, encodeId=b16d1329901fe, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Dec 18 06:14:20 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492534, encodeId=696814925345b, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Dec 18 06:14:20 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
    2022-10-12 fusion
  2. [GetPortalCommentsPageByObjectIdResponse(id=1698307, encodeId=6052169830ea4, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Oct 12 11:14:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779194, encodeId=837a1e7919411, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Mon Jan 17 14:14:20 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778818, encodeId=5a6b1e7881865, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Mon Oct 10 07:14:20 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329901, encodeId=b16d1329901fe, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Dec 18 06:14:20 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492534, encodeId=696814925345b, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Dec 18 06:14:20 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1698307, encodeId=6052169830ea4, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Oct 12 11:14:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779194, encodeId=837a1e7919411, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Mon Jan 17 14:14:20 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778818, encodeId=5a6b1e7881865, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Mon Oct 10 07:14:20 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329901, encodeId=b16d1329901fe, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Dec 18 06:14:20 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492534, encodeId=696814925345b, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Dec 18 06:14:20 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1698307, encodeId=6052169830ea4, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Oct 12 11:14:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779194, encodeId=837a1e7919411, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Mon Jan 17 14:14:20 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778818, encodeId=5a6b1e7881865, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Mon Oct 10 07:14:20 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329901, encodeId=b16d1329901fe, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Dec 18 06:14:20 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492534, encodeId=696814925345b, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Dec 18 06:14:20 CST 2021, time=2021-12-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1698307, encodeId=6052169830ea4, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=43, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Wed Oct 12 11:14:20 CST 2022, time=2022-10-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779194, encodeId=837a1e7919411, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Mon Jan 17 14:14:20 CST 2022, time=2022-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1778818, encodeId=5a6b1e7881865, content=<a href='/topic/show?id=2216130401' target=_blank style='color:#2F92EE;'>#3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1304, encryptionId=2216130401, topicName=3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=416347, createdName=mhzhuang@stu.e, createdTime=Mon Oct 10 07:14:20 CST 2022, time=2022-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1329901, encodeId=b16d1329901fe, content=<a href='/topic/show?id=8f3a19290dd' target=_blank style='color:#2F92EE;'>#ω-3脂肪酸#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19290, encryptionId=8f3a19290dd, topicName=ω-3脂肪酸)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=232a2500033, createdName=1249859em38(暂无昵称), createdTime=Sat Dec 18 06:14:20 CST 2021, time=2021-12-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1492534, encodeId=696814925345b, content=<a href='/topic/show?id=685199141a6' target=_blank style='color:#2F92EE;'>#静脉注射#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=54, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99141, encryptionId=685199141a6, topicName=静脉注射)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=77e28942453, createdName=millore, createdTime=Sat Dec 18 06:14:20 CST 2021, time=2021-12-18, status=1, ipAttribution=)]

相关资讯

Lancet:阿司匹林可降低林奇综合征患者结肠癌风险

林奇综合征与许多肿瘤风险增加相关,尤其是子宫内膜癌。2011年,研究人员在林奇综合征患者中考察了每日服用阿司匹林对肿瘤预防的长期效果,在平均随访55.7个月后,近日研究人员公布了定期服用阿司匹林的长期

Am J Clin Oncol:Meth-ctDNA或是晚期直肠癌潜在的预后标志物

对于局部晚期直肠癌来说,长期预防疾病的转移仍然是一个挑战,并且缺乏强有力的转移性进展的治疗前预后因素。我们推测,基于神经肽Y基因的低甲基化(meth-ctDNA)检测循环肿瘤特异性DNA(ctDNA)

J Clin Oncol:根据UGT1A1基因型定量伊立替康可显著改善晚期直肠癌患者预后

基于尿苷二磷酸葡糖醛酸糖基转移酶1A1(UGT1A1)基因型区分伊立替康剂量可改善病理完全缓解(pCR)率。在该研究中,研究人员进一步研究了术前伊立替康联合以卡培他滨为基础的局部放化疗晚期直肠癌的治疗

World J Gastroenterology:大肠癌患者外周血中单核细胞与淋巴细胞的比率可以作为预后指标

根据最新数据,大肠癌(CRC)是全球第三大最常见的恶性肿瘤。CRC区域淋巴结转移的出现不仅是区域复发发展的重要危险因素,而且是远处转移性病变的发展相关危险因素。远处转移是CRC患者死亡的主要原因。据估

Eur J Heart Fail:肺癌、结肠癌或胰腺癌患者室性心动过速、室性早搏和死亡率的关系

许多癌症患者死于心血管疾病和猝死,但有关室性心律失常患病率和预后意义的数据尚未明确。

新型VEGFR抑制剂Fruquintinib治疗转移性结直肠癌:全球III期试验已经开始

和记黄埔已在美国、欧洲和日本启动了一项全球III期试验(FRESCO-2研究)用于评估Fruquintinib治疗转移性结直肠癌(CRC)的有效性和安全性,首例患者于2020年9月3日在美国服药。